TRANSFUSION TRIAL TO PREVENT PLATELET ALLOIMMUNIZATIONS

对血小板上的抗原进行同种异体免疫是最严重的 血小板输注中的限制因素。在此应用程序中成为 我们是预防异体免疫合作试验的成员 提出两个可能限制同种异体免疫的策略 资料来源：1.治疗急性非淋巴细胞白血病患者。 通过匹配HLA抗原选择血小板捐献者，特别是 所谓的“公共”抗原；2.去除血小板中的白细胞 经过过滤的产品。在一项合作研究中，我们将能够 实施其他战略，如果它们被选中的话。 我们还提出了跟踪同种免疫发展的方法。 与人类白细胞抗原和血小板特异性抗原结合，并确定 同种异体免疫流行病学。

Alloimmunization to antigens on platelets is one of the most severe limiting factors in platelet transfusion. In this application to become a member of a cooperative trial for the prevention of alloimmunization, we propose two strategies which might limit alloimmunization from this source in patients treated for acute non-lymphocytic leukemia: 1. selection of platelet donors by matching HLA antigens, particularly the so-called "public" antigens; 2. removal of leukocytes from platelet products by filtration. In a cooperative study, we would be able to implement other strategies if they were selected. We also propose methods for following the development of alloimmunization to both HLA and platelet-specific antigens and for determining the epidemiology of alloimmunization.